Molecular Innovations Toward Theranostics of Aggressive Prostate Cancer
Annual rept. 1 Sep 2013-31 Aug 2014
TEXAS UNIV AT DALLAS SOUTHWESTERN MEDICAL CENTER
Pagination or Media Count:
In this project, we propose to develop a new drug delivery vehicle based on dendrimer nanotechnology for personalized medicine. This new class of nanoplatforms contains imaging probe and molecular medicine with a cancer-specific targeting capability which is able to target cancer cells, monitor drug delivery and tumor response to achieve a see and treat strategy as a new concept of molecular medicine. Specifically, One Partner PI s lab will make dendrimers bearing functional handles to conjugate with chelating agents provided by the Initiating PI s lab for PET imaging and therapeutic peptides provided by another Partner PI s lab for the treatment of aggressive prostate cancer. In the 2nd year, the Initiating PI s lab has designed and synthesized three enantiopure chelator scaffolds for copper radiopharmaceuticals using a well-validated integrin v 3 ligand. In addition, a theranostic molecular drug conjugate MDC design was accomplished. Such design will be modified and incorporated into the dendrimeric platforms to accomplish further Aims in this project.
- Medicine and Medical Research
- Polymer Chemistry